Rankings
▼
Calendar
ICCC Q4 2024 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena
ICCC
ImmuCell Corporation
$60M
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$8M
+52.1% YoY
Gross Profit
$3M
36.5% margin
Operating Income
$621,395
8.0% margin
Net Income
$514,555
6.6% margin
EPS (Diluted)
$0.06
QoQ Revenue Growth
+28.9%
Cash Flow
Operating Cash Flow
-$3,051
Free Cash Flow
-$199,267
Stock-Based Comp.
$68,863
Balance Sheet
Total Assets
$45M
Total Liabilities
$18M
Stockholders' Equity
$28M
Cash & Equivalents
$4M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$8M
$5M
+52.1%
Gross Profit
$3M
$1M
+125.1%
Operating Income
$621,395
-$1M
+162.0%
Net Income
$514,555
-$1M
+145.1%
Geographic Segments
UNITED STATES
$6M
100%
← FY 2024
All Quarters
Q1 2025 →